Interleukin-7 (IL-7) receptor (IL-7R) signalling complex in human solid tumours

Histology and Histopathology

Volumn 18, Issue 3, 2003, Pages 911-923

  Al Rawi, Mahir A A ^a   Mansel, R E ^a   Jiang, W G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; IL 7; IL 7R; Jaks; Lymphangiogenesis; PI3K; Stats

Indexed keywords

INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 3; LIGAND; PHOSPHATIDYLINOSITOL 3 KINASE; RECOMBINANT INTERLEUKIN 7; STAT PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; B LYMPHOCYTE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; ENZYME PHOSPHORYLATION; EPITHELIUM; GENE THERAPY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HUMAN; HYPERTHERMIC THERAPY; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LEUKEMIA; LUNG CANCER; LUNG METASTASIS; LYMPHOMA; MELANOMA; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE; TUMOR CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BREAST NEOPLASMS; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-7; LIGANDS; MODELS, BIOLOGICAL; NEOPLASMS; PHOSPHORYLATION; RECEPTORS, INTERLEUKIN-7; SIGNAL TRANSDUCTION;

JANUS;

EID: 0037789421     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (158)

1. Akbar A.N., Borthwick N.J., Wickremasinghe R.G., Panayoitidis P., Pilling D., Bofill M., Krajewski S., Reed J.C. and Salmon M. (1996). Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal, selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur. J. Immunol. 26, 294-299.
2. Alderson M. R., Sassenfeld H.M. and Widmer M. B. (1990). Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J. Exp. Med. 172, 577-587.
3. Alderson M.R., Tough T.W., Ziegler S.F. and Grabstein K.H. (1991). Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J. Exp. Med. 173, 923-930.
4. Al-Rawi M., Mansel R. and Jiang W. (2002a). Interlukin-7 (IL-7) and IL-7 Receptor expression in breast cancer. Breast Cancer Res. Treat 76 Supplement 1. S144.
5. Al-Rawi M., Mansel R. and Jiang W. (2002b). Interleukin-7 is a putative lymphangiogenic factor in endothelial cells. Breast Cancer Res. Treat. 76, Supplement 1, S166.
6. Aoki T., Tashiro K., Miyatake S., Kinashi T., Kinashi T., Nakano T., Oda Y., Kikuchi H. and Honjo T. (1992). Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc. Natl. Acad. Sci. USA 89, 3850-3854.
7. Appasamy P.M. (1993). Interleukin-7. Biology and potential clinical applications. Cancer Invest. 11, 487-499.
8. Appasamy P.M. (1999). Biological and clinical implications of interleukin-7 and lymphopoiesis. Cytokines Cell. Mol. Ther. 5, 25-39.
9. Baird A.M., Thomis D.C. and Berg L.J. (1998). T cell development and activation in Jak3-deficient mice. J. Leuk. Biol. 63, 669-677.
10. Benjamin D., Sharma V., Knobloch T.J., Armitage R.J., Dayton M.A. and Goodwin R.G. (1994). B-Cell II-7 - human B-cell lines constitutively secrete II-7 and express II-7 receptors. J. Immunol. 152, 4749-4757.
11. Boise L.H., Minn A.J., June C.H., Linsten T. and Thompson C.B. (1995). Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division. Proc. Natl. Acad. Sci. USA 92, 5491-5495.
12. Bowman T., Garcia R., Turkson J. and Jove R. (2000). STATs in oncogenesis. Oncogene 19, 2474-2488.
13. Bromberg J.F., Horvath C.M., Wen Z., Schreiber R.D and Darnell J.E. Jr. (1996). Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc. Natl. Acad. Sci. USA 93, 7673-7678.
14. Buard A., Vivo C., Monnet I., Boutin C., Pilatte Y. and Jaurand M.C. (1998). Human malignant mesothelioma cell growth activation of janus kinase 2 and s ginal transducer and activator of transcription 1alpha for inhibition by interferon-gamma. Cancer Res. 58, 840-847.
15. Burow M.E., Weldon C.B., Collins-Burow B.M., Ramsey N., McKee A., Klippel A., McLachlan JA., Clejan S. and Beckman B.S. (2000). Cross-talk between phosphatidylinositol 3-kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions. J. Biol. Chem. 275, 9628-9635.
16. Cance W.G. and Liu E.T. (1995). Protein kinases in human breast cancer. Breast Cancer Res Treat 35, 105-114.
17. Cao X., Tay A., Guy G.R. and Tan Y.H. (1996). Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol. Cell. Biol. 16, 1595-603.
18. Cao X.Q., Shores E.W., Huli J., Anver M.R., Kelsall B.L., Paul W.E., Katz S.I., Love P.E. and Leonard W.J. (1995). Defective lymphoid development in mice lacking expression of the common cytokine receptor-gamma chain. Immunity 2, 223-238.
19. Carini C., McLane M.F., Mayer K.H. and Essex M. (1994). Dysregulation of interleukin-7 receptor may generate loss of cytotoxic T cell response in human immunodeficiency virus type 1 infection. Eur. J. Immunol. 24, 2927-2934.
20. Catlett-Falcone R., Dalton WS. and Jove R. (1999). STAT proteins as novel targets for cancer therapy. Signal transducer and activator of transition. Curr Opin. Oncol. 11, 490-496.
21. Cayeux S., Beck S., Aicher A., Dorken B. and Blankenstein T. (1995). Tumor cells cotransfected with interlukin-7 and B7.1 genes induce CD25 and CD28 on tumor infiltrating T lymphocytes and are strong vaccines. Eur J Immunol 25, 2325-2331.
22. Chaturvedi P., Reddy M.V. and Reddy E.P. (1998). Src kinases and hot JAKs activate STATs during IL-3 induced myeloid cell proliferation Oncogene 16, 1749-1758.
23. Chung C.D., Liao J., Liu B., Rao X., Jay P., Berta P. and Shuai K. (1997). Specific inhibition of Stat3 signal transduction by PIAS3. Science 278, 1803-1805.
24. Coffer P.J., Jin J. and Woodgett J.R. (1998). Protein kinase B (c-Akt). A multifuncitonal mediator of phosphatidylinositol 3-kinase activation. Biochem. J. 335, 1-13.
25. Coppola D. (2000). Molecular prognostic markers in pancreatic cancer. Cancer Control 7, 421-427.
26. Cosenza L., Gorgun G., Urbano A. and Foss F. (2002). Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cell Signals 14, 317-325.
27. Costello R., Ibert J. and Olive D. (1993). Interleukin-7, a major T-lymphocyte cytokine. Eur. Cytokine Netw. 4, 253-262.
28. Dadi H., Ke S. and Roifman C.M. (1994). Activation of phosphatidylinositol-3 kinase by ligation of the Interleukin-7 Receptor is Dependent on Protein-Tyrosine Kinase-Activity. Blood 84, 1579-1586.
29. Dalloul A., Laroche L., Bagot M., Mossalayi M.D., Fourcade C., Thacker D.J., Hogge D.E., Merle-Beral H., Debre P. and Schmitt C. (1992). Interleukin-7 is a growth factor for Sezary lymphoma cells. J. Clin. Invest. 90, 1054-1060.
30. Dhir R., Ni Z., Lou W., DeMiguel F., Grandis J.R. and Gao A.C. (2002). Stat3 activation in prostatic carcinomas. Prostate 51, 241-246.
31. Digel W., Schmid M., Heil G., Conrad P., Gillis S. and Porzsolt F. (1991). Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood 78, 753-759.
32. Eder M., Ottmann O.G., Hansen-Hagge T.E., Bartram C.R., Falk S., Gillis S., Hoelzer D. and Ganser A. (1992). In vitro culture of common acute lymphoblastic leukemia blasts. effects of interleukin-3, interleukin-7, and accessory cells. Blood 79, 3274-3284.
33. Eves E.M., Xiong W., Bellacosa A., Kennedy S.G., Tsichlis P.N., Rosner M.R. and Hay N. (1998). Akt, a target of phosphatidylinositol 3-kinase, inhibits apoptosis in a differentiating neuronal cell line. Mol. Cell Biol. 18, 2143-2152.
34. Faltyneck C.R., Wang S., Miller D., Young E., Tiberio L., Kross K., Kelley M. and Kloszewski E. (1992). Administration of human recombinant IL-7 to normal and irradiated mice increases the numbers of lymphocytes and some immature cells of the myeloid lineage. J. Immunol. 149, 1276-1282.
35. Fan S.J., Ma Y.X., Wang J.A., Yuan R.Q., Meng Q.H., Cao Y.J., Laterra J.J., Goldberg I.D. and Rosen E.M. (2000). The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl nositol 3'kinase. Oncogene 19, 2212-2223.
36. Fernandes A., Hamburger A.W. and Gerwin B.I. (1999). ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int. J. Cancer 83, 564-570.
37. Foss H.D., Hummel M., Gottstein S., Ziemann K., Falini B., Herbst H. and Stein H. (1995). Frequent expression of IL-7 gene transcripts in tumor cells of classical Hodgkin's disease. Am. J. Pathol. 146, 33-39.
38. Foxwell B.M.J., Beading C., Guschin D., Kerr I. and Cantrell D (1995). Interleukin-7 can induce the activation of Jak-1, Jak-3 and Stat-5 proteins in Murine T-Cells. Europ. J. Immunol. 25, 3041-3046.
39. Frishman J., Long B., Knospe W., Gregory S. and Plat J. (1993a). Genes for interleukin-7 are transcribed in leukemic-cell subsets of individuals with chronic lymphocytic-leukemia. J. Exp. Med. 177, 955-964.
40. Frishman J., Long B., Knospe W., Gregory S. and Plate J. (1993b). Genes for interleukin-7 are transcribed in leukemic cell subsets of individuals with chronic lymphocytic leukemia. J. Exp. Med. 177, 955-964.
41. Fujihashi K., McGhee J.R., Yamamoto M., Peschon J.J. and Kiyono H. (1997). An interleukin-7 internet for intestinal intraepithelial T cell development. knockout of ligand or receptor reveal differences in the immunodeficient state. Eur. J. Immunol. 27, 2133-2138.
42. Funk P.E., Stephan R.P. and Witte P.L. (1995). Vascular cell adhesion molecule 1-positive reticular cells express interleukin-7 and stem cell factor in the bone marrow. Blood 86, 2661-2671.
43. Garcia R. and Jove R. (1998). Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J. Biomed. Sci. 5, 79-85.
44. Garcia R., Bowman T.L., Niu G., Yu H., Minton S., Muro-Cacho C.A., Cox C.E., Falcone R., Fairclough R., Parsons S., Laudano A., Gazit A., Levitzki A., Kraker A. and Jove R. (2001). Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20, 2499-2513.
45. Garcia R., Yu C.L., Hudnall A., Catlett R., Nelson K.L., Smithgall T., Fujita D.J., Ethier S.P. and Jove R. (1997). Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 8, 1267-1276.
46. Gearing D.P., Druck T., Huebner K., Overhauser J., Gilbert D.J., Copeland N.G. and Jenkins N.A. (1993). The leukemia inhibitory factor receptor (LIFR) gene is located within a cluster of cytokine receptor loci on mouse chromosoma 15 and human chromosome 5p12-p13. Genomics 18, 148-150.
47. Goodwin R.G., Friend D., Ziegler S.F., Jerzy R., Falk B. A., Gimpel S., Cosman D., Dower S. K., March C.J., Namen A. E. and Park L.S. (1990). Cloning of the human and murine interleukin-7 receptors - Demonstration of a soluble form and homology to a new receptor superfamily. Cell 60, 941-951.
48. Goodwin R.G., Lupton S., Schmierer A., Hjerrild K.J., Jerzy R., Clevenger W., Gillis S., Cosman D. and Namen A.E. (1989). Human interleukin-7 - molecular-cloning and growth-factor activity on human and murine B-lineage cells. Proc. Natl. Acad. Sci. USA. 86, 302-306.
49. Gouilleux-Gruart V., Gouilleux F., Desaint C., Claisse J.F., Capiod J.C., Delobel J., Weber-Nordt R., Dusanter-Fourt I., Dreyfus F., Groner B. and Prin L. (1996). STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87, 1692-1697.
50. Grandis J.R., Drenning S.D., Chakraborty A., Zhou M.Y., Zeng Q., Pitt A.S. and Tweardy D.J. (1998). Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J. Clin. Invest. 102, 1385-1392.
51. Green A.R., Green V.L., White M.C. and Speirs V. (1997). Expression of cytokine messenger RNA in normal and neoplastic human breast tissue. Identification of interleukin-8 as a potential regulatory factor in breast tumours. Int. J. Cancer 72, 937-941.
52. Greenlund A.C., Morales M.O., Viviano B.L., Yan H., Krolewski J. and Schreiber R.D. (1995). Stat recruitment by tyrosine-phosphorylated cytokine receptors. an ordered reversible affinity-driven process. Immunity 2, 677-687.
53. Grimley P.M., Fang H., Rui H., Petricoin E.F. III., Ray S., Dong F., Fields K.H., Hu R., Zoon K.C., Audet S. and Beeler J. (1998). Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-alpha. Blood 91, 3017-3027.
54. Gurniak C.B. and Berg L.J. (1996). Murine JAK3 is preferentially expressed in hematopoietic tissues and lymphocyte precursor cells. Blood 87, 3151-3160.
55. Haque S.J., Harbor P., Tabrizi M., Yi T. and Williams B.R. (1998). Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction. J. Biol. Chem. 273, 33893-33896.
56. Hasday J.D., Shah E.M. and Lieberman A.P. (1990). Macrophage tumor necrosis factor-alpha release is induced by contact with some tumors. J. Immunol. 145, 371-379.
57. Hausler P., Papoff G., Eramo A., Reif K., Cantrell D.A. and Ruberti G. (1998). Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B. Eur. J. Immunol. 28, 57-69.
58. Heinrich P. C., Behrmann I., Muller-Newen G., Schafer F. and Graeve L. (1998). Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 334 (Pt 2), 297-314.
59. Heufler C., Topar G., Grasseger A., Stanzl U., Koch F., Romani N., Namen A.E. and Schuler G. (1993). Interleukin-7 is produced by murine and human keratinocytes. J. Exp. Med. 178, 1109-1114.
60. Higuchi M., Asao H., Tanaka N., Oda K., Takeshita T., Nakamura M., VanSnick J. and Sugamura K. (1996). Dispensability of Jak1 tyrosine kinase for interleukin-2 induced cell growth signaling in a human T cell line. Europ. Journal of Immunology 26, 1322-1327.
61. Hilton D.J., Richardson R.T., Alexander W.S., Viney E.M., Willson T.A., Sprigg N.S., Starr R., Nicholson S.E., Metcalf D. and Nicola N.A. (1998). Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. USA 95, 114-119.
62. Hoey T. and Grusby M.J. (1999). STATs as mediators of cytokine-induced responses. Adv. Immunol. 71, 145-162.
63. Hofmeister R., Khaled A.R., Benbernou N., Rajnavolgyi E., Muegge K. and Durum S.K. (1999). Interleukin-7. physiological roles and mechanisms of action. Cytok. Growth Factor Rev. 10, 41-60.
64. Horiguchi A., Oya M., Shimada T., Uchida A., Marumo K. and Murai M. (2002). Activation of signal transducer and activator of transcription 3 in renal cell carcinoma. A study of incidence and its association with pathological features and clinical outcome. J. Urol. 168, 762-765.
65. Huang M., Page C., Reynolds R.K. and Lin J. (2000). Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol. Oncol. 79, 67-73.
66. Hubbard S.R., Wei L., Ellis L. and Hendrickson W.A. (1994). Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372, 746-754.
67. + stage of thymocyte differentiation in the absence of T cell receptor rearrangement. J. Exp. Med. 183, 1923-1928.
68. Jicha D.L., Mule J.J. and Rosenberg S.A. (1991). Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J. Exp. Med. 174, 1511-1515.
69. Jin L., Fuchs A., Schnitt S.J., Yao Y., Joseph A., Lamszus K., Park M., Goldberg I.D. and Rosen E.M. (1997). Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 79, 749-760.
70. Johnston J.A., Bacon C.M., Finbloom D.S., Rees R.C., Kaplan D., Shibuya K., Ortaldo J.R., Gupta S., Chen Y. Q., Gir J.D. and Oshea J.J. (1995). Tyrosine phosphorylation and activation of Stat5, Stat3, and Janus kinases by interleukin-2 and interleukin-15. Proc. Natl. Acad. Sci. USA. 92, 8705-8709.
71. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J. and Schreiber R.D. (1998). Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95, 7556-7561.
72. Kennedy S.G., Wagner A.J., Conzen S.D., Jordan J., Bellacosa A., Tsichlis P.N. and Hay N. (1997). The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 11, 701-713.
73. Klingmuller U., Lorenz U., Cantley L.C., Neel B.G. and Lodish H.F. (1995). Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80, 729-738.
74. Komschlies K.L., Gregorio T.A., Gruys M.E., Back T.C., Faltynek C.R. and Wiltrout R.H. (1994). Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases. J. Immunol. 152, 5776-5584.
75. Kondo M., Takeshita T., Higuchi M., Nakamura M., Sudo T., Nishikawa S.I. and Sugamura K. (1994). Functional participation of the II-2 receptor-gamma chain in II-7 receptor complexes. Science 263, 1453-1454.
76. Kramer G., Steiner G.E., Paiha S., Handisurya A., Djavan B., Mallone R. and Marberger M. (2001). Human accessory cells activate fresh, normal, tumor-distant T lymphocytes but not tumor-infiltrating T lymphocytes to lyse autologous tumor cells in a primary cytotoxic T lymphocyte assay in renal cell carcinoma. Eur. Urol. 40, 427-433.
77. Kroemer R.T., Kroncke R., Gerdes J. and Richards W.G. (1998). Comparison of the 3D models of four different human IL-7 isoforms with human and murine IL-7. Protein Engineering 11, 31-40.
78. Lai K.S., Jin Y., Graha D.K., Witthuhn B.A., Ihle J.N. and Liu E.T. (1995). A kinase-deficient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells. J. Biol. Chem. 270, 25028-25036.
79. Lai S.Y., Molden J. and Goldsmith M.A. (1997). Shared gamma(c) subunit within the human interleukin-7 receptor complex - A molecular basis for the pathogenesis of X-linked severe combined immunodeficiency. J. Clin. Invest. 99, 169-177.
80. Laky K., Lefrancois L., Von Freeden-Jeffry U., Murray R. and Puddington L. (1998). The role of IL-7 in thymic and extrathymic development of TCR gamma delta cells. J. Immunol. 161, 707-713.
81. Leek R.D., Harris A.L. and Lewis C.E. (1994). Cytokine networks in solid human tumors. Regulation of angiogenesis. J. Leukoc. Biol. 56, 423-435.
82. Levy D. E. and Gilliland D.G. (2000). Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene 19, 2505-2510.
83. Lin J.X., Mietz J., Modi W.S., John S. and Leonard W.J. (1996). Cloning of human Stat5B. Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells. J. Biol. Chem. 271, 10738-10744.
84. Lin J.X., Migone T.S., Tsang M., Friedmann M., Weatherbe J.A., Zhou L., Yamauchi A., Bloom E.T., Mietz J., John S. and Leonard W.J. (1995). The role of shared receptor motifs and Common Stat Proteins in the generation of cytokine pleiotropy and redundancy by II-2, II-4, II-7, II-13, and II-15. Immunity 2, 331-339.
85. Liu X., Robinson G.W., Gouilleux F., Groner B and Hennighausen L. (1995). Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc. Natl. Acad. Sci. USA 92, 8831-8835.
86. Liu X., Robinson G.W., Wagner K.U., Garrett L., Wynshaw-Boris A. and Hennighausen L. (1997). Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 11, 179-186.
87. Lynch D.H., Namen A.E. and Miller R.E. (1991). In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes. Eur. J. Immunol. 21, 2977-2985.
88. Maeurer M.J., Walter W., Martin, D., Zitvogel L., Elder, E., Storkus W. and Lotze M.T. (1997). Interleukin-7 (IL-7) in colorectal cancer. IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes. Scand. J. Immunol. 45, 182-192.
89. Maraskovsky E., Teepe M., Morrissey P.J., Braddy S., Miller R.E., Lynch D.H. and Peschon J.J. (1996). Impaired survival and proliferation in IL-7 receptor-deficient peripheral T cells. J. Immunol. 157, 5315-5323.
90. Matsumoto A., Masuhara M., Mitsui K., Yokouchi M., Ohtsubo M., Misawa H., Miyajima A. and Yoshimura A. (1997). CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89, 3148-3154.
91. Matsumoto A., Seki Y., Kubo M., Ohtsuka S., Suzuki A., Hayashi I., Tsuji K., Nakahata T., Okabe M., Yamada S. and Yoshimura A. (1999). Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol. Cell. Biol 19, 6396-6407.
92. Mattei S., Colombo M.P., Melani C., Silvani A., Parmiani G. and Herlyn M. (1994). Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int. J. Cancer 56, 853-857.
93. Migone T.S., Lin J.X., Cereseto A., Mullo J.C., O'Shea J.J., Franchini G. and Leonard W.J. (1995). Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269, 79-81.
94. Miller A.R., McBride W.H., Dubinett S.M., Dougherty G.J., Thacker J.D., Shau H., Kohn D.B., Moen R.C., Walker M.J. and Chiu R. (1993). Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer, comparison of immunologic properties with interleukin-2. Blood 82, 3686-3694.
95. Miyazaki T., Takaoka A., Nogueira L., Dikic I., Fujii H., Tsujino S., Mitani Y., Maeda M., Schlessinger J. and Taniguchi T. (1998). Pyk2 is a downstream mediator of the IL-2 receptor-coupled Jak signaling pathway. Genes Dev. 2, 770-775.
96. Morrissey P.J., Conlon P., Braddy S., Williams D.E., Namen A.E. and Mochizuki D.Y. (1991a). Administration of IL-7 to mice with cyclophosphamide-induced lymphopenia accelerates lymphocyte repopulation. J. Immunol. 146, 1547-1552.
97. Morrissey P.J., Conlon P., Charrier K., Braddy S., Alpert A., Williams D., Namen A.E. and Mochizuki D. (1991b). Administration of IL-7 to normal mice stimulates B-lymphopoiesis and peripheral lymphadenopathy. J. Immunol. 147, 561-568.
98. Murakami M., Narazaki M., Hibi M., Yawata H., Yasukawa K., Hamaguchi M., Taga T. and Kishimoto T. (1991). Critical cytoplasmic region of the interleukin-6 signal transducer Gp130 is conserved in the cytokine receptor family. Proc. Nat. Acad. Sci. USA 88, 11349-11353.
99. Namen A.E., Lupton S., Hjerrild K., Wignall J., Mochizuki D.Y., Schmierer A., Mosley B., March C.J., Urdal D., Gillis S., Cosman D. and Goodwin R.G. (1988a). Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 333, 571-573.
100. Namen A.E., Schmierer A.E., March C.J., Overell R.W., Park L.S., Urdal D.L. and Mochizuki D.Y. (1988b). B cell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. J. Exp. Med. 167, 988-1002.
101. Noguchi M., Nakamura Y., Russell S.M., Ziegler S.F., Tsang M., Cao X.Q. and Leonard W.J. (1993). Interleukin-2 receptor gamma-chain - A functional component of the interleukin-7 receptor. Science 262, 1877-1880.
102. Nosaka T., Vandeursen J.M.A., Tripp R.A., Thierfelder W.E., Witthuhn B.A., McMickle A.P., Doherty P.C., Grosveld G.C. and Ihle J.N. (1995). Defective lymphoid development in mice lacking Jak3. Science 270, 800-802.
103. Oka M., Hirose K., Iizuka N., Aoyagi K., Yamamoto K., Abe T., Hazama S. and Suzuki T. (1995). Cytokine mRNA expression patterns in human esophageal cancer cell lines. J. Interferon Cytokine Res. 15, 1005-1009.
104. Ortmann R.A., Cheng T., Visconti R., Frucht D.M. and O'Shea J.J. (2000). Janus kinases and signal transducers and activators of transcription their roles in cytokine signaling, development and immunoregulation. Arthritis Res 2, 16-32.
105. Page T.H., Lali F.V. and Foxwell B.M.J. (1995). Interleukin-7 activates P56(Lck) and P59(Fyn), 2 tyrosine kinases associated with the p90 interleukin-7 receptor in primary human T-cells. Eur. J. Immunol. 25, 2956-2960.
106. Paleri V., Pulimood A., Davie G.R. and Birchall M.A. (2001). Interleukins 7 and 12 are expressed in head and neck squamous cancer. Clin. Otolaryngol. 26, 302-306.
107. Pansky A., Hildebrand P., Fasler-Kan E., Baselgia L., Ketterer S., Beglinger C. and Heim M.H. (2000). Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int. J. Cancer 85, 720-725.
108. Park L.S., Friend D.J., Schmierer A.E., Dower S.K. and Namen A.E. (1990). Murine interleukin 7 (IL-7) receptor. Characterization on an IL-7-dependent cell line. J. Exp. Med. 171, 1073-1079.
109. Pernis A., Gupta S., Yopp J., Garfein E., Kashleva H., Schindler C.and Rothman P. (1995). Gamma-chain-associated cytokine receptors signal through distinct transducing factors. J. Biol. Chem. 270, 14517-14522.
110. Pezet A., Favre H., Kelly P.A. and Edery M. (1999). Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling. J. Biol. Chem. 274, 24497-24502.
111. Pivniouk V., Tsitsikov E., Swinton P., Rathbun G., Alt F.W. and Geha R.S. (1998). Impaired viability and profound block in thymocyte development in mice lacking the adaptor protein SLP-76. Cell 94, 229-238.
112. Potocnik A., Nielsen P.J. and Eichmann K. (1994). In vitro generation of lymphoid precursors from embryonic stem cells. EMBO J. 13, 5274-5283.
113. Qin J.Z., Zhang C.L., Kamarashev J., Dummer R., Burg G. and Dobbeling U. (2001). Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood 98, 2778-2783.
114. Ray R.J., Furlonger C., Williams D.E. and Paige C.J. (1996). Characterization of thymic stromal-derived lymphopoietin (TSLP) in murine B cell development in vitro. Eur. J. Immunol. 26, 10-16.
115. Rich B.E., Campos-Torres J., Tepper R.I., Moreadith R.W. and Leder P. (1993). Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J. Exp. Med. 177, 305-316.
116. Rosenthal L.A., Winestock K.D. and Finbloom D.S. (1997). IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts. Cell. Immunol. 181, 172-181.
117. Rowan S. and Fisher D.E. (1997). Mechanisms of apoptotic cell death. Leukemia 11, 457-465.
118. Saito S., Harada N., Ishii N., Morii T., Sakakura S., Enomoto M., Umekage H., Nishikawa K., Narita N., Nakamura M., Sugamura K. and Morikawa H. (1997). Functional expression on human trophoblasts of interleukin 4 and interleukin 7 receptor complexes with a common gamma chain. Biochem. Biophys. Res. Commun. 231, 429-434.
119. Sartor C.I., Dziubinski M.L., Yu C.L., Jove R. and Ethier S.P. (1997). Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res. 57, 978-987.
120. Seckinger P. and Fougereau M. (1994). Activation of Src family kinases in human Pre-B cells by II-7. J. Immunol. 153, 97-109.
121. Sharma S., Miller P.W., Stolina M., Zhu L., Huang M., Paul R.W. and Dubinett S.M. (1997). Multicomponent gene therapy vaccines for lung cancer. Effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells. Gene Ther 4, 1361-1370.
122. Sharma S., Wang J., Huang M., Paul R.W., Lee P., McBride W.H., Economou J.S., Roth M.D., Kiertscher S.M. and Dubinett S.M. (1996). Interleukin-7 gene transfer in non-small-cell lung cancer decreases tumor proliferation, modifies cell surface molecule expression, and enhances antitumor reactivity. Cancer Gene Ther. 3, 302-313.
123. Sica D., Rayman P., Stanley J., Edinger M., Tubbs R.R., Klein E., Bukowski R. and Finke J.H. (1993). Interleukin 7 enhances the proliferation and effector function of tumor-infiltrating lymphocytes from renal-cell carcinoma. Int. J. Cancer 53, 941-947.
124. Silva M.R., Hoffman R., Srour E.F. and Ascensao J.L. (1994). Generation of human natural killer cells from immature progenitors does not require marrow stromal cells. Blood 84, 841-846.
125. Soloff R.S., Wang T.F., Dempsey D., Jennings S.R., Wolcott R.M. and Chervenak R. (1997). Interleukin 7 induces TCR gene rearrangement in adult marrow-resident murine precursor T cells. Mol. Immunol. 34, 453-462.
126. Sun M., Paciga J.E., Feldman R.I., Yuan Z.Q., Coppola D., Lu Y.Y., Shelley S.A., Nicosia S.V. and Cheng J.Q. (2001). Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ER alpha) via interaction between ER alpha and PI3K. Cancer Res. 61, 5985-5991.
127. Sweeney E.B., Foss F.M., Murphy J.R. and VanderSpek J.C. (1998). Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7. A novel agent for the elimination of IL-7 receptor positive cells. Bioconjug. Chem. 9, 201-207.
128. Takakuwa T., Nomura S., Matsuzuka F., Inoue H. and Aozasa K. (2000). Expression of interleukin-7 and its receptor in thyroid lymphoma. Lab. Invest. 80, 1483-1490.
129. Takeshita T., Arita T., Asao H., Tanaka N., Higuchi M., Kuroda H., Kaneko K., Munakata H., Endo Y., Fujita T. and Sugamura K. (1996). Cloning of a novel signal-transducing adaptor molecule containing an SH3 domain and ITAM. Biochem. Biophys. Res. Commun. 225, 1035-1039.
130. Takeshita T., Arita T., Higuchi M., Asao H., Endo K., Kuroda H., Tanaka N., Murata K., Ishii N. and Sugamura K. (1997). STAM, signal transducing adaptor molecule, is associated with Janus kinases and involved in signaling for cell growth and c-myc induction. Immunity 6, 449-457.
131. Takeuchi T., Yamanouchi H., Yue Q. and Ohtsuki Y. (1998). Epithelial component of lymphoid stroma-rich Warthin's tumour expresses interleukin (IL)-7. Histopathology 32, 383-384.
132. Talmadge J.E., Jackson J.D., Kelsey L., Borgeson C.D., Faltynek C. and Perry G.A. (1993). T-cell reconstitution by molecular, phenotypic, and functional analysis in the thymus, bone marrow, spleen, and blood following split-dose polychemotherapy and therapeutic activity for metastatic breast cancer in mice. J. Immunother. 14, 258-268.
133. Taniguchi T. and Minami Y. (1993). The IL-2/IL-2 receptor system. A current overview. Cell 73, 5-8.
134. Thomis D.C., Gurniak C.B., Tivol E., Sharpe A.H. and Berg L.J. (1995). Defects in B-lymphocyte maturation and T-lymphocyte activation in mice lacking Jak3. Science 270, 794-797.
135. Toker A. and Cantley L.C. (1997). Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 387, 673-676.
136. Touw I., Pouwels K., Van Agthoven T., Van Gurp R., Budel L., Hoogerbrugge H., Delwel R., Goodwi R., Namen A. and Lowenberg B. (1990). Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood 75, 2097-2101.
137. Trinder P., Seitzer U., Gerdes J., Seliger B. and Maeurer M. (1999). Constitutive and IFN-gamma regulated expression of IL-7 and IL-15 in human renal cell cancer. Int. J. Oncol. 14, 23-31.
138. Trumper L., Jung W., Dahl G., Diehl V., Gause A. and Pfreundschuh M. (1994). Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann. Oncol. 5 Suppl 1, 93-96.
139. Van Der Plas D.C., Smiers F., Pouwels K., Hoefsloot L.H., Lowenberg B. and Touw I.P. (1996). Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain. Leukemia 10, 1317-1325.
140. Vanhaesebroeck B., Leevers S.J., Panayotou G. and Waterfield M.D. (1997). Phosphoinositide 3-kinases. A conserved family of signal transducers. Trends Biochem. Sci. 22, 267-272.
141. Venkitaraman A.R. and Cowling R.J. (1992). Interleukin-7 receptor functions by recruiting the tyrosine kinase P59(Fyn) through a segment of its cytoplasmic tail. Proc. Natl. Acad. Sci. USA 89, 12083-12087.
142. Von Freeden-Jeffry U., Vieira P., Lucian L.A., McNei T., Burdach S.E. and Murray R. (1995). Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J. Exp. Med. 181, 1519-1526.
143. Watanabe M., Ueno Y., Yajima T., Iwao Y., Tsuchiya M., Ishikawa H., Aiso S., Hibi T. and Ishii H. (1995). Interleukin-7 is produced by human intestinal epithelial-cells and regulates the proliferation of intestinal mucosal lymphocytes. J. Clin. Investigation 95, 2945-2953.
144. Watson C.J. and Miller W.R. (1995). Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br. J. Cancer 71, 840-844.
145. Weber-Nordt R.M., Egen C., Wehinger J., Ludwig W., Gouilleux-Gruart V., Mertelsmann R. and Finke J. (1996). Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88, 809-816.
146. Wen X., Lin H.H., Shih H.M., Kung H.J. and Ann D.K. (1999). Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactive STAT-mediated gene expression in salivary and lung epithelial cells. J. Biol. Chem. 274, 38204-38210.
147. Wiles M.V., Ruiz P. and Imhof B.A. (1992). Interleukin-7 expression during mouse thymus development. Eur. J. Immunol. 22, 1037-1042.
148. Wong B.R., Besser D., Kim N., Arron J.R., Vologodskaia M., Hanafusa H. and Choi Y. (1999). TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell 4, 1041-1049.
149. Wu B., Shen R.N., Wang W.X., Broxmeyer H.E. and Lu L. (1993). Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells. Stem Cells 11, 412-421.
150. Yamada K., Shimaoka M., Nagayama K., Hiroi T., Kiyono H. and Honda T. (1997). Bacterial invasion induces interleukin-7 receptor expression in colonic
151. Yamashita J., Ogawa M., Yamashita S., Nomura K., Kuramoto M., Saishoji T. and Shin S. (1994). Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. 54, 1630-1633.
152. Ye B.H., Cattoretti G., Shen Q., Zhang J., Hawe N., De Waard R., Leung C., Nouri-Shirazi M., Orazi A., Chaganti R.S., Rothman P., Stall A.M., Pandolfi P.P. and Dalla-Favera R. (1997). The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat. Genet. 16, 161-170.
153. Yoshimura A., Ohkubo T., Kiguchi T., Jenkins N.A., Gilbert D.J., Copeland N.G., Hara T. and Miyajima A. (1995). A novel cytokine-inducible gene CIS encodes an SH2-containg protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14, 2816-2826.
154. Yu C.L., Meyer D.J., Campbell G.S., Larner A.C., Carter-Su C., Schwartz J. and Jove R. (1995). Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269, 81-83.
155. Zeng Y.X., Takahashi H., Shibata M. and Hirokawa K. (1994). Jak3 janus linase is involved in interleukin-7 signal pathway. FEBS Lett. 353, 289-293.
156. Zhang Q., Nowak I., Vonderheid E.C., Rook A.H., Kadin M.E., Nowell P.C., Shaw L.M. and Wasik M.A. (1996). Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc. Natl. Acad. Sci. USA 93, 9148-9153.
157. Zong C., Yan R., August A., Darnell J.E., Jr. and Hanafusa H. (1996). Unique signal transduction and Eyk. constitutive stimulation of the JAK-STAT pathway by an oncogenic receptor-type tyrosine kinase. EMBO J. 15, 4515-4525.
158. Zong C.S., Zeng L., Jiang Y., Sadowski H.B. and Wang L.H. (1998). Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth. J. Biol. Chem. 273, 28065-28072.